Cyplasin Biomedical Ltd Announces Second U.S. Patent for Cyplasin

06-Nov-2007

Cyplasin Biomedical Ltd today announced that its U.S. Patent application Nr 10/501,098 entitled "Cytotoxic Cyplasin of the Sea Hare, Aplysia punctata, cDNA cloning and Expression of Bioreactive Recombinants" has been granted as US patent Number US 7,271,242 B2. The patent claims cover the production of a cytotoxic protein by mammalian cells and its use to treat cancer.

"This patent is an important milestone to define our intellectual property for the production method of the cytotoxic cyplasin and related proteins and its application as a substance to treat cancer. With the two US patents now in our possession, the Company will concentrate all its efforts to achieve a fast and successful development of cyplasin", said Professor Christian Petzelt, Chief Scientific Officer of Cyplasin Biomedical Ltd.

Other news from the department research and development

Most read news

More news from our other portals

So close that even
molecules turn red...